Addex gets $1M MJFF grant to test potential dyskinesia drug

03/20/2013 | Pharmaceutical Business Review Online

The Michael J. Fox Foundation awarded Addex Therapeutics a $1 million grant to support clinical trials of dipraglurant against levodopa-induced dyskinesia among Parkinson's disease patients. Dipraglurant, an oral, small molecule allosteric modulator, selectively inhibits metabotropic glutamate receptor 5.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC